NCT03690388Phase 3Active not recruiting

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Study sponsor: Exelixis

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-08-19Actual
Enrollment · participants187Actual
Source updated2026-10-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.